Valuation Arrowhead Pharmaceuticals, Inc.
Equities
ARWR
US04280A1007
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 62.64 USD | -2.91% |
|
-14.19% | -5.65% |
| 02-09 | Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 - Biotechnology | CI |
| 02-09 | Arrowhead Pharmaceuticals, Inc.(NasdaqGS:ARWR) added to S&P 400 Health Care | CI |
Company Valuation: Arrowhead Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: September | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,509 | 3,498 | 2,880 | 2,408 | 4,769 | 8,772 | - | - |
| Change | - | -46.25% | -17.67% | -16.4% | 98.03% | 83.95% | - | - |
| Enterprise Value (EV) 1 | 6,141 | 3,390 | 2,769 | 2,305 | 3,961 | 7,872 | 7,590 | 7,955 |
| Change | - | -44.79% | -18.31% | -16.76% | 71.8% | 98.76% | -3.58% | 4.81% |
| P/E ratio | -45.9x | -19.8x | -14x | -3.87x | -3,449x | -18.1x | -15.1x | -19x |
| PBR | 15.9x | 8.79x | 10.6x | 13x | 10x | 16.3x | 12.2x | 23.5x |
| PEG | - | -0.9x | -0.9x | -0x | 34.6x | -0x | -0.7x | 0.9x |
| Capitalization / Revenue | 47.1x | 14.4x | 12x | 678x | 5.75x | 19.1x | 27.7x | 17.5x |
| EV / Revenue | 44.4x | 13.9x | 11.5x | 649x | 4.77x | 17.1x | 24x | 15.8x |
| EV / EBITDA | -43.6x | -20.2x | -14.4x | -3.96x | 32.4x | -24x | -14.5x | -13x |
| EV / EBIT | -41.2x | -19x | -13.5x | -3.84x | 40.3x | -18.7x | -12.5x | -14.7x |
| EV / FCF | 41.6x | -17.9x | -8.38x | -3.81x | 25.2x | -32.6x | -15.5x | -18.9x |
| FCF Yield | 2.4% | -5.57% | -11.9% | -26.2% | 3.96% | -3.07% | -6.44% | -5.29% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -1.36 | -1.67 | -1.92 | -5 | -0.01 | -3.454 | -4.161 | -3.293 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 138.3 | 243.2 | 240.7 | 3.551 | 829.4 | 459.4 | 316.5 | 502.6 |
| EBITDA 1 | -140.8 | -168.1 | -192.5 | -582.5 | 122.3 | -327.6 | -523.4 | -613.9 |
| EBIT 1 | -149 | -178.5 | -205 | -601.1 | 98.35 | -420.3 | -609.4 | -541.1 |
| Net income 1 | -140.8 | -176.1 | -205.3 | -599.5 | -1.631 | -494.5 | -601.9 | -486 |
| Net Debt 1 | -367.8 | -108 | -110.9 | -102.7 | -808 | -899.7 | -1,182 | -816.3 |
| Reference price 2 | 62.43 | 33.05 | 26.87 | 19.37 | 34.49 | 62.64 | 62.64 | 62.64 |
| Nbr of stocks (in thousands) | 104,259 | 105,849 | 107,193 | 124,315 | 138,258 | 140,032 | - | - |
| Announcement Date | 22/11/21 | 28/11/22 | 29/11/23 | 26/11/24 | 25/11/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -18.14x | 17.14x | -24.03x | -.--% | 8.77B | |
| 47.35x | 11.16x | 40.25x | 0.02% | 51.1B | |
| 17.07x | 6.09x | 13.4x | 1.75% | 42.55B | |
| -25.66x | 51.65x | -29.33x | -.--% | 31.89B | |
| -27.1x | 4.66x | -12.85x | -.--% | 27.69B | |
| 31.55x | 6.19x | 17.17x | -.--% | 20.25B | |
| 16.38x | 3.83x | 10.13x | -.--% | 18.95B | |
| -174.05x | 42.86x | -173.66x | -.--% | 12.51B | |
| -307.98x | 24.19x | 1017.84x | -.--% | 11.99B | |
| 16.62x | 4.79x | 11.63x | -.--% | 11.83B | |
| Average | -42.39x | 17.26x | 87.06x | 0.18% | 23.75B | |
| Weighted average by Cap. | -13.92x | 16.15x | 49.81x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ARWR Stock
- Valuation Arrowhead Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition